Abdo A. Elfiky

Citation:

Ezat, A. A., J. M. Abduljalil, A. M. Elghareib, A. Samir, and A. A. Elfiky, "The discovery of novel antivirals for the treatment of mpox: is drug repurposing the answer?", Expert Opinion on Drug Discovery, vol. 18, issue 5, pp. 551 - 561, 2023.

Abstract:

Introduction: Drugs that have demonstrated good activity against any member of the Orthopoxvirus genus are good candidates for repurposing studies against the mpox virus (MPXV). The conserved biology of poxviruses has proven beneficial from a clinical virology perspective. Evolutionarily conserved proteins tend to function in a highly similar way. Indeed, the smallpox vaccine was found to be 85% effective in protecting humans from mpox virus infection. Similarly, tecovirimat, the drug of choice for smallpox infections, was recently repurposed as a treatment option for mpox cases in Europe. Area covered: This review article focuses on drug repurposing strategies to combat the newly emerged MPXV outbreak. The viral and host cell protein targets are challenged with a bunch of drugs and drug-like molecules in silico, in vitro, and in vivo. Some drugs show promising results and can be repurposed to eradicate MPXV infection. The authors also highlight potential limitations and provide their expert perspectives. Expert opinion: Overall, it is clear that we cannot solely rely on the conventional drug discovery pipeline to find new treatments, despite advances in computational and experimental advances in the last few decades. Drug repurposing has successfully identified good candidate drugs against MPXV as it is one of the Orthopoxvirus genus family. Tecovirimat, brincidofovir, and cidofovir have shown promising results in preventing virus propagation. Consequently, drug repurposing represents an important strategy for the fast identification of new therapeutic options. © 2023 Informa UK Limited, trading as Taylor & Francis Group.

Notes:

Export Date: 24 May 2024; Cited By: 7

Related External Link